Omicron subvariants: New study gives Evusheld and Sotrovimab the thumbs-up

[bennevisplace]

An in vitro study of several antibody therapies by Japanese researchers found diminished neutralisation of the Omicron variant and particularly of the BA.2 subvariant. Now a study at Washington University indicates that Evusheld and Sotrovimab both retain neutralising activity, while reducing viral load and lung inflammation in mice.

reuters.com/business/health...

This is the pre-print publication of the research findings, not peer reviewed. NB competing interest statement and concluding section Limitations of Study. biorxiv.org/content/10.1101...

[CaptRon1976]

Very good newsI had EVUSHELD in January with my “top up” to 300mg this month.

Good to have some confidence from it whilst remaining very cautious.

I don’t respond well enough to the pneumonia vaccines either, wish their were “EVUSHELD-like” antibodies for pneumococcal pneumonia.

Ron

[Yuck]

Thank you for posting — very encouraging!Best,

Yuck